AD17002 Adjuvant and Immunotherapy Technology Platform
Advagene's patented technology platform, which is applied to the development of new drugs for mucosal adjuvant and mucosal immunotherapy. The development of products includes nasal spray influenza vaccine, asthma immunotherapy, respiratory allergy immunotherapy, COVID-19 & other antiviral immunotherapy, etc.
Dual Immune Defense
Induces both mucosal and systemic immunity to intercept pathogens at the entry point, providing broader protection than traditional injections.
Immune Rebalancing
Restores immune balance by modulating Th2 cytokines. It targets the root cause of inflammation rather than just managing symptoms.
Versatile Technology Platform
A versatile platform for diverse applications, including vaccine adjuvants, respiratory antivirals, asthma, and dermatology.
Research & Development
The R&D portfolio of Advagene Biopharma Co., Ltd. includes nasal spray vaccines for seasonal flu and COVID-19, alongside immunotherapies for allergy, COVID-19, RSV, and rhinovirus-induced asthma. Our expertise covers the entire development lifecycle, from initial discovery and preclinical research to Phase I–III clinical trials and commercialization. At Advagene, our mission has always been to safeguard health worldwide.
Learn more about our Pipeline
Intranasal Vaccines
A non-invasive, needle-free platform inducing both mucosal and systemic immunity. Validated in Phase II flu trials for its safety and broad-spectrum protective potential.
Explore more
Asthma Immunotherapy
Targeting eosinophilic asthma by rebalancing immune responses and Th2 cytokines. Clinically proven to improve lung function and address the underlying cause of inflammation.
Explore more
Respiratory Antiviral Immunotherapy
First-in-class mucosal therapy neutralizing viruses at the point of entry. Clinically proven to reduce viral load and accelerate recovery for respiratory infections.
Explore more
Partners
